: its prevalence, pathogenicity and increasing resistance to fluconazole Free

Abstract

has been identified as the most prevalent pathogenic yeast species of the -non- group. Historically, has been the major species responsible for causing candidiasis in immunocompromised and immunocompetent patients. However, infections (candidiasis) due to have increased dramatically on a global scale thus proclaiming this organism to be an emerging pathogenic yeast. The reasons for this organism's dominance and its resistance to fluconazole have been difficult to elucidate. In addition, the mechanism of this organism's pathogenicity and the consequent immune response remain to be clarified. This paper describes certain predisposing factors potentially responsible for these characteristics and presents a ‘root cause analysis' to explain the increasing prevalence of in developed and undeveloped countries, as well as the organism's acquired drug resistance. Control measures against fluconazole resistance in clinical management have also been discussed.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.013227-0
2010-08-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/8/873.html?itemId=/content/journal/jmm/10.1099/jmm.0.013227-0&mimeType=html&fmt=ahah

References

  1. Anil S., Samaranayake L. P. 2003; Brief exposure to antimycotics reduces the extracellular phospholipase activity of Candida albicans and Candida tropicalis . Chemotherapy 49:243–247 [CrossRef]
    [Google Scholar]
  2. Antonopoulou S., Aoun M., Alexopoulos E. C., Baka S., Logothetis E., Kalambokas T., Zannos A., Papadias K., Grigoriou O. other authors 2009; Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes. Antimicrob Agents Chemother 53:2181–2184 [CrossRef]
    [Google Scholar]
  3. Barchiesi F., Calabrese D., Sanglard D., Falconi Di Francesco L., Caselli F., Giannini D., Giacometti A., Gavaudan S., Scalise G. 2000; Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother 44:1578–1584 [CrossRef]
    [Google Scholar]
  4. Barnett J. A., Payne R. W., Yarrow D. 1990 Yeasts: Characteristics and Identification , 2nd edn. Cambridge: Cambridge University Press;
    [Google Scholar]
  5. Bodey G. P. 1984; Candidiasis in cancer patients. Am J Med 77:13–19
    [Google Scholar]
  6. Borg M., Rüchel R. 1990; Demonstration of fungal proteinase during phagocytosis of Candida albicans and Candida tropicalis . J Med Vet Mycol 28:3–14 [CrossRef]
    [Google Scholar]
  7. Borg-von Zepelin M., Beggah S., Boggian K., Sanglard D., Monod M. 1998; The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol Microbiol 28:543–554 [CrossRef]
    [Google Scholar]
  8. Brun S., Bergès T., Poupard P., Vauzelle-Moreau C., Renier G., Chabasse D., Bouchara J.-P. 2004; Mechanisms of azole resistance in petite mutants of Candida glabrata . Antimicrob Agents Chemother 48:1788–1796 [CrossRef]
    [Google Scholar]
  9. Buesching W. J., Kurek K., Roberts G. D. 1979; Evaluation of the modified API 20C system for identification of clinically important yeasts. J Clin Microbiol 9:565–569
    [Google Scholar]
  10. Cantorna M. T., Balish E. 1990; Mucosal and systemic candidiasis in congenitally immunodeficient mice. Infect Immun 58:1093–1100
    [Google Scholar]
  11. Capobianco J. O., Lerner C. G., Goldman R. C. 1992; Application of a fluorogenic substrate in the assay of proteolytic activity and in the discovery of a potent inhibitor of Candida albicans aspartic proteinase. Anal Biochem 204:96–102 [CrossRef]
    [Google Scholar]
  12. Clark R. A., Blakley S. A., Rice J., Brandon W. 1995; Predictors of HIV progression in women. J Acquir Immune Defic Syndr Hum Retrovirol 9:43–50
    [Google Scholar]
  13. Davis S. L., Vazquez J. A., McKinnon P. S. 2007; Epidemiology, risk factors, and outcomes of Candida albicans versus non- albicans candidemia in nonneutropenic patients. Ann Pharmacother 41:568–573 [CrossRef]
    [Google Scholar]
  14. Dixon T. C., Steinbach W. J., Benjamin D. K. Jr, Williams L. W., Myers L. A. 2004; Disseminated Candida tropicalis in a patient with chronic mucocutaneous candidiasis. South Med J 97:788–790 [CrossRef]
    [Google Scholar]
  15. Ellis M. 2002; Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Mol Immunol 38:947–957 [CrossRef]
    [Google Scholar]
  16. Fromtling R. A., Abruzzo G. K., Giltinan D. M. 1987; Candida tropicalis infection in normal, diabetic, and neutropenic mice. J Clin Microbiol 25:1416–1420
    [Google Scholar]
  17. Fung J. J. 2002; Fungal infections in liver transplantation. Transpl Infect Dis 4:18–23 [CrossRef]
    [Google Scholar]
  18. Gokce G., Cerikcioglu N., Yagci A. 2007; Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood cultures. Mycopathologia 164:265–269 [CrossRef]
    [Google Scholar]
  19. González-Gravina H., González-de Morán E., Zambrano O., Lozano-Chourio M., Rodríguez-de Valero S., Robertis S., Mesa L. 2007; Oral Candidiasis in children and adolescents with cancer. Identification of Candida spp. Med Oral Patol Oral Cir Bucal 12:E419–E423
    [Google Scholar]
  20. Gronemeyer P. S., Weissfeld A. S., Sonnenwirth A. C. 1982; Purulent pericarditis complicating systemic infection with Candida tropicalis . Am J Clin Pathol 77:471–475
    [Google Scholar]
  21. Gruber A., Lell C. P., Spruth M., Lass-Flörl C., Speth C., Stoiber H., Hube B, Coleman D, Polonelli L. other authors 2003; HIV-1 and its transmembrane protein gp41 bind to different Candida species modulating adhesion. FEMS Immunol Med Microbiol 37:77–83 [CrossRef]
    [Google Scholar]
  22. Hsueh P. R., Lau Y. J., Chuang Y. C., Wan J. H., Huang W. K., Shyr J. M., Yan J. J., Yu K. W., Wu J. J. other authors 2005; Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans , and Aspergillus species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 49:512–517 [CrossRef]
    [Google Scholar]
  23. Husain S., Tollemar J., Dominguez E. A., Baumgarten K., Humar A., Paterson D. L., Wagener M. M., Kusne S., Singh N. 2003; Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75:2023–2029 [CrossRef]
    [Google Scholar]
  24. Imam N., Carpenter C. C. J., Mayer K. H., Fisher A., Stein M., Danforth S. B. 1990; Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am J Med 89:142–146 [CrossRef]
    [Google Scholar]
  25. Jacobs P. H., Nall L. (editors) 1990; Antifungal Drug Therapy: a Complete Guide for the Practitioner . pp 32–45 New York: Marcel Dekker;
  26. Jorge A. O. C., Totti M. A. G., de Almeida O. P., Scully C. 1993; Oral candidiasis established in the sialoadenectomised rat. J Oral Pathol Med 22:54–56 [CrossRef]
    [Google Scholar]
  27. Joseph-Horne T., Hollomon D. W. 1997; Molecular mechanisms of azole resistance in fungi. FEMS Microbiol Lett 149:141–149 [CrossRef]
    [Google Scholar]
  28. Kao A. S., Brandt M. E., Pruitt W. R., Conn L. A., Perkins B. A., Stephens D. S., Baughman W. S., Reingold A. L., Rothrock G. A. other authors 1999; The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 29:1164–1170 [CrossRef]
    [Google Scholar]
  29. Khazim R. M., Debnath U. K., Fares Y. 2006; Candida albicans osteomyelitis of the spine: progressive clinical and radiological features and surgical management in three cases. Eur Spine J 15:1404–1410 [CrossRef]
    [Google Scholar]
  30. Kirkpatrick C. H. 1989; Chronic mucocutaneous candidiasis. Eur J Clin Microbiol Infect Dis 8:448–456 [CrossRef]
    [Google Scholar]
  31. Kirkpatrick C. H., Rich R. R., Bennett J. E. 1971; Chronic mucocutaneous candidiasis: model building in cellular immunity. Ann Intern Med 74:955–978 [CrossRef]
    [Google Scholar]
  32. Kontoyiannis D. P., Vaziri I., Hanna H. A., Boktour M., Thornby J., Hachem R., Bodey G. P., Raad I. I. 2001; Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 33:1676–1681 [CrossRef]
    [Google Scholar]
  33. Kothari A., Sagar V. 2009; Epidemiology of Candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol 27:171–172 [CrossRef]
    [Google Scholar]
  34. Kothavade R. J., Panthaki M. H. 1998; Evaluation of phospholipase activity of Candida albicans and its correlation with pathogenicity in mice. J Med Microbiol 47:99–102 [CrossRef]
    [Google Scholar]
  35. Krasner R. I. 2002 Concepts of microbial disease. In The Microbial Challenge: Human–Microbe Interactions , chapter 6 pp 103–120 Washington, DC: American Society for Microbiology;
    [Google Scholar]
  36. Krawczyk B., Leibner-Ciszak J., Mielech A., Nowak M., Kur J. 2009; PCR melting profile (PCR MP) – a new tool for differentiation of Candida albicans strains. BMC Infect Dis 9:177 [CrossRef]
    [Google Scholar]
  37. Myerowitz R. L., Pazin G. J., Allen C. M. 1977; Disseminated candidiasis: changes in incidence, underlying diseases, and pathology. Am J Clin Pathol 68:29–38
    [Google Scholar]
  38. Myoken Y., Kyo T., Fujihara M., Sugata T., Mikami Y. 2004; Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies. Haematologica 89:378–380
    [Google Scholar]
  39. Ng K. P., Madasamy M., Saw T. L., Baki A., He J., Soo-Hoo T. S. 1998; Candida biotypes isolated from clinical specimens in Malaysia. Mycopathologia 144:135–140 [CrossRef]
    [Google Scholar]
  40. Nissapatorn V., Lee C., Fatt Q. K., Abdullah K. A. 2003; AIDS-related opportunistic infections in Hospital Kuala Lumpur. Jpn J Infect Dis 56:187–192
    [Google Scholar]
  41. Nucci M., Colombo A. 2007; Candidemia due to Candida tropicalis : clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis 58:77–82 [CrossRef]
    [Google Scholar]
  42. Odds F. C. 1988; Chronic mucocutaneous candidiosis. In Candida and Candidosis pp 104–110 Baltimore, MD: University Park Press;
    [Google Scholar]
  43. Okumura Y., Inoue N., Nikai T. 2007; Isolation and characterization of a novel acid proteinase, tropiase from Candida tropicalis IFO 0589. Nippon Ishinkin Gakkai Zasshi 48:19–25 [CrossRef]
    [Google Scholar]
  44. Parthiban C. J. K. B., Majeed S. A., Mahalingam S. S. 2008; Candida tropicalis spondylodiskitis in a patient with carcinoma of sigmoid colon: a case report. Cases J 1:66 [CrossRef]
    [Google Scholar]
  45. Paya C. V. 1993; Fungal infections in solid-organ transplantation. Clin Infect Dis 16:677–688 [CrossRef]
    [Google Scholar]
  46. Perfect J. R. 2004; Antifungal resistance: the clinical front. Oncology (Williston Park) 18 (Suppl. 13):S15–S22
    [Google Scholar]
  47. Pfaller M. A., Boyken L., Hollis R. J., Kroeger J., Messer S. A., Tendolkar S., Diekema D. J. ARTEMIS DISK Global Antifungal Surveillance Group 2009; Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 65:27–34 [CrossRef]
    [Google Scholar]
  48. Prasad K. N., Agarwal T., Dixit A. K., Tiwari D. P., Dhole T. N., Ayyagari A. 1999; Role of yeast as nosocomial pathogens and their susceptibilities to fluconazole and amphotericin B. Indian J Med Res 110:11–17
    [Google Scholar]
  49. Rhoads J. L., Wright D. C., Redfield R. R., Burke D. S. 1987; Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA 257:3105–3107 [CrossRef]
    [Google Scholar]
  50. Roilides E., Farmaki E., Evdoridou J., Francesconi A., Kasai M., Filioti J., Tsivitanidou M., Sofianou D., Kremenopoulos G., Walsh T. J. 2003; Candida tropicalis in a neonatal intensive care unit: epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen. J Clin Microbiol 41:735–741 [CrossRef]
    [Google Scholar]
  51. Rüchel R. 1986; Cleavage of immunoglobulins by pathogenic yeasts of the genus Candida . Microbiol Sci 3:316–319
    [Google Scholar]
  52. Rüchel R., Böning B., Borg M. 1986; Characterization of a secretory proteinase of Candida parapsilosis and evidence for the absence of the enzyme under conditions of infection in vitro. Infect Immun 53:411–419
    [Google Scholar]
  53. Rüchel R., Zimmermann F., Böning-Stutzer B., Helmchen U. 1991; Candidiasis visualized by proteinase-directed immunofluorescence. Virchows Arch A Pathol Anat Histopathol 419:199–202 [CrossRef]
    [Google Scholar]
  54. Sandford G. R., Merz W. G., Wingard J. R., Charache P., Saral R. 1980; The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 142:503–509 [CrossRef]
    [Google Scholar]
  55. Sanglard D., Odds F. C. 2002; Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2:73–85 [CrossRef]
    [Google Scholar]
  56. Schrank J. H. Jr, Dooley D. P. 1995; Purulent pericarditis caused by Candida species: case report and review. Clin Infect Dis 21:182–187 [CrossRef]
    [Google Scholar]
  57. Shiraki Y., Ishibashi Y., Hiruma M., Nishikawa A., Ikeda S. 2008; Candida albicans abrogates the expression of interferon-gamma-inducible protein-10 in human keratinocytes. FEMS Immunol Med Microbiol 54:122–128 [CrossRef]
    [Google Scholar]
  58. Sim J. P., Kho B. C., Liu H. S., Yung R., Chan J. C. 2005; Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J 11:120–123
    [Google Scholar]
  59. Singh A., Bairy I., Shivananda P. G. 2003; Spectrum of opportunistic infections in AIDS cases. Indian J Med Sci 57:16–21
    [Google Scholar]
  60. Stein D. K., Sugar A. M. 1989; Fungal infections in the immunocompromised host. Diagn Microbiol Infect Dis 12:221S–228S
    [Google Scholar]
  61. Stone H. H., Kolb L. D., Cume C. A., Geheber C. E., Cuzzell J. Z. 1974; Candida sepsis: pathogenesis and principles of treatment. Ann Surg 179:697–711 [CrossRef]
    [Google Scholar]
  62. Tortorano A. M., Rigoni A. L., Biraghi E., Prigitano A., Viviani M. A. FIMUA-ECMM Candidemia Study Group 2003; The European Confederation of Medical Mycology (ECMM) survey of candidemia in Italy: antifungal susceptibility patterns of 261 non- albicans Candida isolates from blood. J Antimicrob Chemother 52:679–682 [CrossRef]
    [Google Scholar]
  63. Vazquez J. A., Sobel J. D. 1995; Fungal infections in diabetes. Infect Dis Clin North Am 9:97–116
    [Google Scholar]
  64. Verma A. K., Prasad K. N., Singh M., Dixit A. K., Ayyagari A. 2003; Candidaemia in patients of a tertiary health care hospital from north India. Indian J Med Res 117:122–128
    [Google Scholar]
  65. Vermitsky J. P., Edlind T. D. 2004; Azole resistance in Candida glabrata : coordinate up-regulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother 48:3773–3781 [CrossRef]
    [Google Scholar]
  66. Walsh T. J., Merz W. G. 1986; Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis . Am J Clin Pathol 85:498–502
    [Google Scholar]
  67. Weinberger M., Sacks T., Sulkes J., Shapiro M., Polacheck I. 1997; Increasing fungal isolation from clinical specimens: experience in a university hospital over a decade. J Hosp Infect 35:185–195
    [Google Scholar]
  68. White M. H. 1996; Is vulvovaginal candidiasis an AIDS-related illness. Clin Infect Dis 22:S124–S127 [CrossRef]
    [Google Scholar]
  69. Wingard J. R., Merz W. G., Saral R. 1979; Candida tropicalis : a major pathogen in immunocompromised patients. Ann Intern Med 91:539–543 [CrossRef]
    [Google Scholar]
  70. Wingard J. R., Dick J. D., Merz W. G., Sandford G. R., Saral R., Burns W. H. 1980; Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice. Infect Immun 29:808–813
    [Google Scholar]
  71. Winston D. J., Pakrasi A., Busuttil R. W. 1999; Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131:729–737
    [Google Scholar]
  72. Yang Y. L., Ho Y. A., Cheng H. H., Ho M., Lo H. J. 2004; Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis . Infect Control Hosp Epidemiol 25:60–64 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.013227-0
Loading
/content/journal/jmm/10.1099/jmm.0.013227-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed